MRSN · As filed with the SEC
Mersana Therapeutics income statement, by quarter
The statement as Mersana Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 |
|---|---|---|---|---|
| Collaboration revenue | 11,009 | 3,056 | 2,754 | 16,361† |
| Operating expenses: | ||||
| Research and development | 12,182 | 16,218 | 18,341 | 22,286† |
| General and administrative | 6,303 | 7,415 | 8,925 | 8,886† |
| Restructuring expenses | 191 | 3,940 | — | 0† |
| Total operating expenses | 18,676 | 27,573 | 27,266 | 31,172† |
| Other income (expense): | ||||
| Interest income | 516 | 895 | 1,164 | 1,597† |
| Interest expense | (394) | (674) | (775) | (903)† |
| Total other income, net | 122 | 221 | 389 | 694† |
| Loss before income taxes | (7,545) | — | — | (14,117)† |
| Income tax expense | 0 | — | — | 0† |
| Net loss | (7,545) | (24,296) | (24,123) | (14,117)† |
| Other comprehensive loss | ||||
| Unrealized gain (loss) on marketable securities, net of tax | 0 | 0 | (10) | (15)† |
| Comprehensive loss | (7,545) | (24,296) | (24,133) | (14,132)† |
| Net loss attributable to common stockholders — basic | (7,545) | (24,296) | (24,123) | (14,117)† |
| Net loss attributable to common stockholders — diluted | (7,545) | (24,296) | (24,123) | (14,117)† |
| Net loss per share attributable to common stockholders — basic (in dollars per share) | (1.51) | (4.87) | (0.19) | — |
| Net loss per share attributable to common stockholders — diluted (in dollars per share) | (1.51) | (4.87) | (0.19) | — |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — basic (in shares) | 4,992,639 | 4,986,784 | 124,466,113 | — |
| Weighted-average number of shares of common stock used in net loss per share attributable to common stockholders — diluted (in shares) | 4,992,639 | 4,986,784 | 124,466,113 | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.